funding
Technogenesys, Inc. is undertaking Phase I clinical trial in early 2025. It has received funding to run a Phase I Clinical Trial (acronym: PHAROS) from NIH/NCI (RO1 CA286443).
It is currently raising `A’ round of investment to do Phase II clinical trial for (R)-9b inhibitor. Interested parties, VC groups and pharma companies are welcome to get in touch with us. We have extensive dataset which is available for due diligence. Our contact info is shown below:
Technogenesys, Inc. is at the forefront of developing `dual’ inhibitor (i) tackling cancer drug resistance, and (ii) activating host immune response
Key reasons for investing in TechnoGenesys:
- We are the first developer of `dual’ prostate cancer drug – a rapidly developing therapeutic area with a huge market
- High unmet medical need: 1.4 million new cases of prostate cancer and over 375,000 related deaths were reported in 2020 globally. Large majority of all cancer related deaths are due to drug resistance
- First-in-class: There are currently no ACK1 inhibitor on the market, and our compound (R)-9b is first in this class.
- De-risked clinical asset with multiple upcoming value inflection points: Initial clinical proof-of-concept expected in Q1, 2025 (First-in-human, phase I) and completion of phase Ib trial is expected in Q1, 2026
- Highly focused clinical development: Focused early-stage dataset for value creation with opportunities to broaden into 3 other cancer indications (breast and lung cancer)
- Experienced leadership: Leadership team with clear track record from biotech and pharma and a prominent clinical advisory board
- Comprehensive patent protection: We have secured long patent protection (until at least 2035) of our lead asset and we are diligently expanding and strengthening our portfolio of intellectual property rights
